New drug shows promise for rare genetic disorder in kids

NCT ID NCT07593391

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This phase 3 study is testing an oral drug called NNZ-2591 in 180 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition that causes developmental delays and other challenges. The main goal is to see if the drug is safe and tolerable over the long term. Researchers will also check if it helps improve symptoms using a special assessment scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NNZ-2591 (an oral drug taken twice daily)
What this could lead to
If successful, this could provide a long-term treatment option to help manage symptoms and improve daily functioning in children with Phelan-McDermid syndrome.
What could go wrong
This is an open-label extension study, meaning everyone knows they are getting the drug, which can bias results. The trial focuses on safety and may not prove the drug works better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHELAN-MCDERMID SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Neuren PMS-302 Site#104

    RECRUITING

    Lexington, Massachusetts, 02421, United States

  • Neuren PMS-302 Site#108

    RECRUITING

    Cincinnati, Ohio, 02421, United States

  • Neuren PMS-302 Site#109

    RECRUITING

    Chevy Chase, Maryland, 20815, United States

  • Neuren PMS-302 Site#111

    RECRUITING

    San Rafael, California, 94903, United States

  • Neuren PMS-302 Site#115

    RECRUITING

    Houston, Texas, 77030, United States

  • Neuren PMS-302 Site#122

    RECRUITING

    Glendale, California, 91203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.